Andra AP fonden Raises Stake in Amgen Inc. $AMGN

Andra AP fonden raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 306.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 47,200 shares of the medical research company’s stock after buying an additional 35,600 shares during the quarter. Andra AP fonden’s holdings in Amgen were worth $13,320,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. West Family Investments Inc. grew its stake in Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after acquiring an additional 30 shares in the last quarter. TAGStone Capital Inc. boosted its holdings in Amgen by 0.8% in the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after purchasing an additional 32 shares during the period. BBR Partners LLC boosted its holdings in Amgen by 0.5% in the 3rd quarter. BBR Partners LLC now owns 7,117 shares of the medical research company’s stock valued at $2,008,000 after purchasing an additional 32 shares during the period. JFS Wealth Advisors LLC grew its position in shares of Amgen by 3.2% during the 3rd quarter. JFS Wealth Advisors LLC now owns 1,070 shares of the medical research company’s stock valued at $302,000 after purchasing an additional 33 shares in the last quarter. Finally, Wealth Quarterback LLC increased its holdings in shares of Amgen by 1.6% in the third quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock worth $624,000 after purchasing an additional 34 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Up 2.3%

Shares of NASDAQ AMGN opened at $388.16 on Friday. The firm’s fifty day moving average is $348.89 and its 200 day moving average is $319.48. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $390.14. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The company has a market cap of $209.25 billion, a price-to-earnings ratio of 27.28, a PEG ratio of 3.76 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter in the prior year, the company posted $5.31 EPS. The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 2.6%. Amgen’s payout ratio is 70.84%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported a new evolocumab bioavailability study that refines dosing/PK assessment for its PCSK9 cholesterol franchise, signaling management’s continued investment in a long‑lived cardiovascular product line and potential lifecycle optimization. Amgen Fine-Tunes Evolocumab
• Positive Sentiment: Amgen advanced maridebart (cafraglutide) toward a Phase 2b obesity and liver‑fat trial — news that expands the company’s obesity pipeline and supports upside potential beyond core biologics. Pipeline progress tends to lift pharma multiples. Amgen Advances Maridebart
• Positive Sentiment: Coverage and momentum narratives are supportive — Zacks highlights AMGN as a top long‑term momentum stock, which can attract trend‑driven and fund flows. Why Amgen is a Top Momentum Stock
• Positive Sentiment: Market headlines note AMGN reaching an all‑time high and outperforming the Dow recently — reinforcement for bullish sentiment and potential technical buying. Amgen stock hits all-time high Is Amgen Stock Outperforming the Dow?
• Neutral Sentiment: Biotech sector activity: a large biotech IPO (Generate Biomedicines) indicates healthy capital markets for life sciences, which can be a neutral tailwind for large biotech names but doesn’t directly change Amgen’s fundamentals. Generate caps a strong month for biotech IPOs
• Neutral Sentiment: Minor portfolio rebalancing: a small sale by Bradley Foster & Sargent reduced a modest position in AMGN — not material to shares outstanding or sentiment. Bradley Foster & Sargent sells AMGN
• Negative Sentiment: Policy risk: a proposed U.S. bill to tighten rules on corporate inversions mentions AMGN among companies potentially affected by changes to international tax treatment — could raise longer‑term tax/structural uncertainty if enacted. Impact is uncertain and likely small near term. Stop Corporate Inversions Act of 2026
• Neutral Sentiment: Reported short‑interest data in feeds looks inconsistent (zeros/NaN) and should be treated with caution; no clear signal from short interest trends. (data sources above).

Analyst Ratings Changes

Several research firms recently issued reports on AMGN. Truist Financial lifted their price objective on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. Deutsche Bank Aktiengesellschaft lifted their price target on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Argus upped their price objective on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Wells Fargo & Company raised their target price on shares of Amgen from $325.00 to $375.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. Finally, Royal Bank Of Canada boosted their price target on shares of Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $351.76.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.